Advances and complications of regenerative medicine in diabetes therapy

摘要: The rapid development of technologies in regenerative medicine indicates clearly that their common application is not a matter if, but when. However, the regeneration beta-cells for diabetes patients remains complex challenge due to plurality related problems. Indeed, generation masses expressing marker genes only first step, with maintaining permanent insulin secretion, protection from immune system and avoiding pathological modifications genome being necessary next developments. prospects therapy were promoted by emergence promising results embryonic stem cells (ESCs). Their pluripotency proliferation an undifferentiated state during culture have ensured success ESCs medicine. discovery induced pluripotent (iPSCs) derived patients' own mesenchymal has provided further hope treatment. Nonetheless, use significant limitations stage, such as risk teratomas. Thus, direct conversion mature into could address this issue. Recent studies shown possibility transdifferentiation set trends medicine, directed at minimizing invasive procedures. In review, we will discuss published beta-cell advantages disadvantages illustrated these experiments.